Marked Chart Marked Chart Closed

The Marked Chart Wire · Health

VK2735

Viking Therapeutics reports VK2735 trial results showing BMI improvements

Viking Therapeutics announced that 74 percent of participants taking subcutaneous VK2735 improved their BMI category after 13 weeks, compared with 15 percent on placebo. The company also noted improvements in cardiometabolic markers.

VKTX-1.3%

Illustration for the Health desk

The stocks in this story

  1. VKTX-1.3%Viking$25.84

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.

New to this? Read: Reading a stock chart

More Health news

Illustration for the Health desk

Biohaven

Biohaven shares phase 1 results for BHV-1530

Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.